Philadelphia, PA (PRWEB) January 06, 2014
ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, today announced an expansion to its cardiac safety, respiratory, and Clinical Outcome Assessment (COA)/electronic COA (eCOA) consulting group. Matthew Reaney joins ERT as a scientific and regulatory consultant, broadening the COA/eCOA expertise ERT delivers to the global biopharmaceutical industry.
As a Senior Scientist, Matt brings to ERT a wealth of first-hand experience in designing, implementing, and leveraging COAs – with considerable focus on Patient Reported Outcomes (PROs) – in drug development and in clinical practice. He has in-depth knowledge of current trends in the regulatory, payer and healthcare environments that affect COA research.
“ERT offers the most reliable, experience-driven, and comprehensive consulting in the industry,” said Matt Reaney. “I’m honored to join this group of pioneering scientists as they continue to deliver targeted, knowledgeable services to support biopharmaceutical and academic researchers in meeting regulatory guidance, payer demands and healthcare needs.”
Matt is a Chartered and Practitioner Health Psychologist, a Fellow of both the Royal Societies of Medicine and Public Health, and an Associate Fellow of the British Psychological Society. He joins ERT from Eli Lilly & Company, where over the past five years he held European and Global positions in the organization’s Health Outcomes research group, conducting clinical trial and real-world research. Matt will draw from this experience as he delivers strategic and tactical COA consulting services from ERT’s regional office in England.
“Matt’s real-world outcomes research experience as well as his extensive knowledge of the European landscape nicely complements our proven scientific and regulatory expertise in the issues pertaining to COA strategy development and implementation,” said Dr. Chad Gwaltney, ERT’s Sr. Director of Consulting Services. “We welcome him to our team and look forward to the valuable insight he will deliver to our global customers.”
ERT’s consulting group harnesses the industry-leading expertise and unrivaled experience of its cardiac safety, respiratory and COA scientific thought leaders to support the clinical development needs of biopharmaceutical researchers. With the addition of Matt Reaney, ERT’s consulting group will strengthen its capabilities in supporting global biopharmaceutical researchers who seek regulatory approval and commercial optimization for new medical treatments in development.
ERT’s consulting group has published a white paper, “Clinical Outcome Assessments: Planning for Success,” which outlines the steps biopharmaceutical researchers can take to ensure their COA strategies meet regulatory guidance and their commercial objectives. The paper is available for free download at http://www.ert.com/clinical/resources/white-papers/COA.
To learn more about ERT’s scientific and regulatory consulting, visit http://www.ert.com/clinical/clinical-endpoints/clinical-research-consulting/.
ERT (http://www.ert.com) is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle. ERT delivers the most widely deployed solutions in centralized cardiac safety, respiratory services, suicide risk assessment and Clinical Outcome Assessments (COAs) – which includes patient, clinician, and observer reported outcomes. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes, and delivers safety and efficacy data critical to the approval, labeling, and reimbursement of pharmaceutical products. ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., U.K., Japan, and Germany.